{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:46:28Z","timestamp":1792525588978,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.medj.2025.100784","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T14:41:50Z","timestamp":1754664110000},"page":"100784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy without resolution: A critical appraisal of mepolizumab in eosinophilic COPD"],"prefix":"10.1016","volume":"6","author":[{"given":"Mario","family":"Cazzola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Matera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2025.100784_bib1","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1056\/NEJMoa2413181","article-title":"Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype","volume":"392","author":"Sciurba","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100784_bib2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/ACI.0000000000000251","article-title":"Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs","volume":"16","author":"Varricchi","year":"2016","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.medj.2025.100784_bib3","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/17512433.2021.1925537","article-title":"Classes of drugs that target the cellular components of inflammation under clinical development for COPD","volume":"14","author":"Matera","year":"2021","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.medj.2025.100784_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/14712598.2022.2160238","article-title":"Biologic therapies for chronic obstructive pulmonary disease","volume":"23","author":"Matera","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.medj.2025.100784_bib5","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100784_bib6","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2147\/COPD.S294333","article-title":"Mepolizumab for eosinophil-associated COPD: Analysis of METREX and METREO","volume":"16","author":"Pavord","year":"2021","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.medj.2025.100784_bib7","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s40265-025-02188-8","article-title":"Chronic obstructive pulmonary disease (COPD): Developments in pharmacological treatments","volume":"85","author":"Singh","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.medj.2025.100784_bib8","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2025 Report. https:\/\/goldcopd.org\/2025-gold-report\/."},{"key":"10.1016\/j.medj.2025.100784_bib9","first-page":"363","article-title":"An overview of the safety and efficacy of monoclonal antibodies for the chronic obstructive pulmonary disease","volume":"15","author":"Cazzola","year":"2021","journal-title":"Biologics"},{"key":"10.1016\/j.medj.2025.100784_bib10","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1172\/JCI85664","article-title":"Lung-resident eosinophils represent a distinct regulatory eosinophil subset","volume":"126","author":"Mesnil","year":"2016","journal-title":"J. Clin. Investig."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025002119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025002119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T22:39:43Z","timestamp":1756247983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634025002119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2666634025002119"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2025.100784","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy without resolution: A critical appraisal of mepolizumab in eosinophilic COPD","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2025.100784","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100784"}}